



## Elanco deal triggers Starpharma SPP extension

**Melbourne; 11 May 2009:** The Board of Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today.

Starpharma has already received SPP acceptances in excess of A\$1.1 million, with the SPP due to close on Wednesday, 13 May 2009. The SPP will now close at 5.00 pm (AEST) on Friday, 15 May 2009.

The extension is intended to provide eligible shareholders\* with the opportunity to consider the Elanco announcement and the significance of this partnership, and in view of the existing closing date, to provide sufficient time to respond.

No action is required to be taken by shareholders who have already made application for shares under the SPP. However if you wish to increase your participation, promptly telephone either Computershare on 1300 507 903 or Starpharma on +61 3 8532 2704.

The other terms of the SPP, including the price of A\$0.26 per share and the maximum application value of A\$10,000 per shareholder, remain as set out in the offer document mailed to shareholders on 23 April 2009. The revised timetable of key dates for the SPP is now as follows (all times are AEST):

Record Date	7 pm, Tuesday 7 April 2009
Opening Date	Thursday 23 April 2009
Closing Date	5 pm, Friday 15 May 2009
Allotment of Shares	Friday 22 May 2009
Trading of New Shares expected to commence on ASX	Monday 25 May 2009
Holding statements expected to be dispatched to shareholders	Wednesday 27 May 2009

\*As previously advised, Australian and New Zealand registered shareholders who held shares at 7.00 pm (AEST) on the record date of 7 April 2009 are eligible to participate in the SPP.

### About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGa.

The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE:SSL) to develop a VivaGel® coated condom. SSL manufactures and sells Durex® condoms, the market-leading condom brand worldwide. Starpharma's receipts under the agreement are estimated to exceed A\$100m comprising royalties on SSL sales, further milestone payments, and development support.

In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science applications including water remediation.

### For further information:

Media Buchan Consulting		Starpharma <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b>	<b>Ellie Papathanasiou</b>	<b>Dr Jackie Fairley</b>	<b>Ben Rogers</b>
Tel: +61 3 9866 4722 Mob: +61 417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>	Tel: +61 2 9237 2800 <a href="mailto:epapathanasiou@bcg.com.au">epapathanasiou@bcg.com.au</a>	Chief Executive Officer +61 3 8532 2704	Company Secretary +61 3 8532 2702 <a href="mailto:ben.rogers@starpharma.com">ben.rogers@starpharma.com</a>